SCHEMBL31395367

SCHEMBL31395367

Cc1ccc(S(=O)(=O)n2cc(-c3cc(F)cnc3Oc3ccc(F)cc3)c3ccn(C)c(=O)c32)cc1

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 16/20 0.47
▸ EED O75530 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31395483 0.94 BRD4 (0.54) BRD4
SCHEMBL31395287 0.89 BRD4 (0.45) BRD4EEDMEN1KMT2A
SCHEMBL31395339 0.83 BRD4 (0.54) BRD4
SCHEMBL31395392 0.82 BRD4 (0.53) BRD4MEN1KMT2A
SCHEMBL31395418 0.82 BRD4 (0.46) BRD4EEDMEN1KMT2A
SCHEMBL31395475 0.81 BRD4 (0.45) BRD4KMT2A
SCHEMBL31395489 0.79 BRD4 (0.59) BRD4
SCHEMBL31395468 0.78 BRD4 (0.52) BRD4
SCHEMBL15067765 0.77 BRD4 (0.62) BRD4
SCHEMBL17492642 0.77 BRD4 (0.53) BRD4EEDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739307-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY The General Hospital Corporation (US) 2026-05-13 — — EP disclosed
WO-2025010291-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY THE GENERAL HOSPITAL CORPORATION (US) 2025-01-09 — — WO disclosed
Send feedback